In AML, low-risk TP53 mutations (RFS > −1) were associated with median OS of 12.9 months, versus 5.5 months for high-risk (RFS ≤ −1) variants, further indicating patients who would benefit from intensive treatment approaches [53]. Here, TP53 is linked to acute myeloid leukemia.